China Isotope & Radiation Corporation (HKG:1763)

Market Cap	6.75B +79.7%
Revenue (ttm)	8.00B -5.1%
Net Income	364.36M -19.5%
EPS	1.14 -19.8%
Shares Out	319.87M
PE Ratio	18.59
Forward PE	n/a
Dividend	0.43 (2.02%)
Ex-Dividend Date	Jun 23, 2026

Volume	62,000
Average Volume	171,360
Open	20.52
Previous Close	20.58
Day's Range	20.06 - 21.24
52-Week Range	10.38 - 25.00
Beta	0.56
RSI	51.89
Earnings Date	Mar 27, 2026

About China Isotope & Radiation

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of nuclides, diagnostic, and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Other Businesses. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmace...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1983
• Employees: 3,361
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1763

Financial Performance

In 2025, China Isotope & Radiation's revenue was 7.19 billion, a decrease of -5.11% compared to the previous year's 7.57 billion. Earnings were 327.43 million, a decrease of -19.48%.

Financial numbers in CNY